PCI Biotech - Fundamentale forhold (PCIB)

[TekBot]

PCI Biotech to present at RNA Therapeutics Virtual Conference

Oslo (Norway), 22 January 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that it will present at the
…

Vis børsmeldingen

12(th) Annual RNA Therapeutics Virtual Conference, a UK based online event
taking place February 10-11, 2021. The 2021 conference is set to explore the
latest developments in RNA delivery agents and RNA-based therapeutics with the
latest case studies on advanced mRNA technologies, oligonucleotide delivery,
therapeutic applications and future trends and innovations. PCI Biotech is also
a sponsor of the event.

On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will
present an overview of PCI Biotech’s proprietary platform technology, focusing
on the delivery of RNA molecules, including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies.
The presentation slides will be made available through a separate press release
around the timing of the presentation and the full presentation will be made
available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific
publications & presentations” after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[magga]

" including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies."

skulle vel tro dette gjelder PCIB/AZ samarbeidet?

[Stupet]

‘‘The presentation slides will be made available through a separate press release around the timing of the presentation …’’
Ja, skal de presentere noe børssensitivt?

[Investor]

@magga

skulle vel tro dette gjelder PCIB/AZ samarbeidet?

Definitivt. Da får vi de vite mer om de nye indikasjonene også utenfor kreft.

[Jubel]

Pcib fimaVacc (PCIB)

Jeg ved ikke hvem som fandt denne men den er ganske interessant i forhold til Pcib. I korte trækk viser det at der kan være problemer med noe av innholdet i de lipider som leverer covid 19 vaccine fra Moderna og Pfizer/Biontec - Specifikt polyethylene glycol (PEG), som er en del av lipidet og øker stabiliteten og livs lengden til lipidet. Det man er redd for er at immunforsvaret skal bli immun overfor PEG (danne antistoffer mot), som vil bety at man ikke kan bruke dette lengere. Studier har…

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @lenny (1555 likes)

@lenny

Jeg vet mange er lei AZ-PCIB snakk, vil fokusere videre, og legge dette bak seg. Jeg lover at dette er mitt siste innlegg om AZ, men jeg klarte ikke å holde meg borte fra å spekulere en siste gang, slik at det er sagt. Der er nemlig en logisk og vesentlig brist i forklaringene som er gitt på Q, podcaster og børsmeldingen. Jeg har hørt gjennom flere ganger, og det er noe som ikke stemmer.

2. @Jubel (1173 likes)

@Jubel

Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers

3. @bamse (908 likes)

@bamse

Jeg tror Professor Sjoerd van der Burg kan vise seg å bli en nøkkelperson for PCIB.

Resten av topp 10:

4. @Investor (773 likes)

5. @Durable (556 likes)

6. @solo (374 likes)

7. @Sorlendingen (362 likes)

8. @ufo (359 likes)

9. @polygon (359 likes)

10. @abacus (342 likes)

Gratulerer!

[TekBot]

PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation

Oslo (Norway), 10 February 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today released the fimaNAc focused presentation
…

Vis børsmeldingen

for the 12(th) Annual RNA Therapeutics Virtual Conference, a UK based online
event taking place February 10-11, 2021. The 2021 conference is set to explore
the latest developments in RNA delivery agents and RNA-based therapeutics with
the latest case studies on advanced mRNA technologies, oligonucleotide delivery,
therapeutic applications and future trends and innovations. PCI Biotech is also
a sponsor of the event.

Today, Wednesday February 10 2021, at 13:10pm (CET) Dr. Anders Høgset, CSO, will
present an overview of PCI Biotech’s proprietary platform technology, focusing
on the delivery of RNA molecules, including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies.

Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical
results have recently been achieved with the fimaNAc technology and we are very
pleased to be able to share these data now. The rapid development progress of
mRNA-based vaccines against Covid-19 has generated much attention to the
potential of nucleic acid therapeutics generally, and mRNA particularly. The
results with fimaNAc suggests that this technology provides an appealing
intracellular delivery solution for certain applications within this class of
therapeutics.

An online recording of the full presentation held by Dr Høgset will be made
available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific
publications & presentations” after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[theroger]

Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical results have recently been achieved with the fima NAc technology and we are very pleased to be able to share these data now. The rapid development progress of mRNA-based vaccines against Covid-19 has generated much attention to the potential of nucleic acid therapeutics generally, and mRNA particularly. The results with fima NAc suggests that this technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics.

[Hod]

INTRATUMOURAL DELIVERY WITH fimaNAC IS CONVINCINGLY SUPERIOR TO LNPS

For en konferanse å komme med ett slikt utsagn!

[Investor]

fimaNAC with 3 µg mRNA increased luciferase activity about 35 times as compared to the LNPs

[danron10]

“In vivo, fimaNAc - mediated local enhancement of siRNA effect has been demonstrated in tumours and in SKIN”

Boom!

[Shqipe]

An online recording of the full presentation held by Dr Høgset will be made available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific publications & presentations” after the event.

Gleder meg til å se den

[vegar_beider]

ABG Sundal Collier - PCI Biotech Holding ASA (PCIB) PCI Biotech - New fimaNAc...

[Jubel]

ABG har vel heller ikke inkludert Asia markedet i RELEASE studien (og er ikke det flere tusen nye pasienter årlig)…?

Samtidig skriver de lovende proof of concept data (mRNA)

Kursmål er 37kr.

Og 0 verdi tydeligvis på Vacc og Nac. I og med de skriver økt potensialet etter resultater for potensielle Nac avtaler

[Ebitor]

Synes 37 er et greit kursmål Jubel.
Tross alt 9 kr over dagens aksjekurs.
Husk alle monner drar ‍♂

[olafalo]

Although gene insertion into macrophages has proven difficult, the results presented here show that non-viral transfection of the [cytosine deaminase prodrug activating] CD gene into these immune cells can be enhanced via PCI. CD transfected NR8383 cells could efficiently convert 5-FC to 5-FU and export the drug, producing a pronounced bystander toxic effect on adjacent non-transfected glioma cells. Compared to single treatment, repetitive PCI-induced transfection was more efficient at low CD plasmid concentration.

Photodiagnosis and Photodynamic Therapy, March 2021. Enhanced gene transfection of macrophages by photochemical internalization: Potential for gene-directed enzyme prodrug therapy of gliomas. Authors:Gabrielle Romena, Lina Nguyen (University of California, Irvine), Kristian Berg (Oslo University Hospital) Steen J. Madsen, Henry Hirschberg.

[Shqipe]

PCI presentation RNA Therapeutics Feb 2021:
https://player.vimeo.com/video/513321075

[TekBot]

PCI Biotech: Invitation to fourth quarter 2020 results presentation

Oslo, Norway, 18 February 2021 - PCI Biotech’s (OSE: PCIB) fourth quarter and
preliminary full year 2020 interim report will be released on 24 February 2021
at 07.00 CET. The interim report and presentation will be made available on
…

Vis børsmeldingen

www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

A results presentation (in English) will be held through a live webcast at
08.30 CET the same day. The webcast can be accessed through www.pcibiotech.com.
There will be a Q&A session at the end of the presentation. It will be possible
to post written questions through the webcast console or through a
teleconference facilitated for investors intending to ask questions verbally
during the Q&A session.

For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[solskimm]

@Mani

Stå opp tidlig i morgen selg PciB og alt inn i Nanov
Neste uke Nanov raser forbi PciB

Jeg vet ikke om du er klar over hva du akkurat har gjort?!
Nå har du hele PCIB-gjengen etter deg, you can run but you can’t hide;

We don’t have money. But what we do have are a very particular set of skills; skills we have acquired over a very long career. Skills that make us a nightmare for people like you. If you let PCIB go now, that’ll be the end of it. We will not look for you, we will not pursue you. But if you don’t, we will look for you, we will find you, and we will tickle you.

[solskimm]

Men det er i beste fall dårlig stil å kjøre manøveren du gjør her og nå!

@Savepig kommer vel å rydder opp i fundamentaltråden